Compare VEEV & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEEV | RPRX |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4B | 22.0B |
| IPO Year | 2013 | 2020 |
| Metric | VEEV | RPRX |
|---|---|---|
| Price | $172.55 | $55.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 5 |
| Target Price | ★ $280.42 | $51.40 |
| AVG Volume (30 Days) | 2.4M | ★ 3.1M |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | ★ 25.93 | N/A |
| EPS | ★ 5.44 | 0.67 |
| Revenue | $1,104,081,000.00 | ★ $2,378,193,000.00 |
| Revenue This Year | $14.42 | $38.63 |
| Revenue Next Year | $12.17 | $4.73 |
| P/E Ratio | ★ $32.67 | $82.19 |
| Revenue Growth | ★ 28.05 | 5.06 |
| 52 Week Low | $148.05 | $33.37 |
| 52 Week High | $310.50 | $56.01 |
| Indicator | VEEV | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 67.93 |
| Support Level | $172.59 | $35.35 |
| Resistance Level | $184.71 | N/A |
| Average True Range (ATR) | 8.14 | 1.16 |
| MACD | 1.98 | 0.02 |
| Stochastic Oscillator | 52.14 | 93.81 |
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.